Press Releases

Investors

E-mail Alerts

Oct 8, 2018

Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)

VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia)

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 4, 2018

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018

Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 1, 2018

Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting

Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Sep 26, 2018

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Sep 20, 2018

Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...